Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
93,08 EUR | +1,35% | +5,57% | +3,70% |
29/04 | SANOFI : Deutsche Bank is niet overtuigd | ZD |
29/04 | SANOFI : JP Morgan handhaaft het Neutraal advies | ZD |
Vakgebied
- Farmaceutische producten (70,6%): geneesmiddelen op recept op het gebied van de gespecialiseerde geneeskunde (59,3% van de omzet; voor de behandeling van multiple sclerose, neurologische ziekten, ontstekingsziekten, auto-immuunziekten, zeldzame ziekten, kankers en zeldzame bloedziekten) en de algemene geneeskunde (40,7%; hoofdzakelijk voor de behandeling van diabetes en hart- en vaatziekten);
- menselijke vaccins (17,4%): vaccins voor kinderen, tegen griep, meningitis en polio, herinneringsvaccins en vaccins bestemd voor reizigers naar inheemse gebieden;
- gezondheidsproducten voor de consument (12%).
Eind 2023 beschikte het concern wereldwijd over 54 productiesites.
De geografische verdeling van de omzet is als volgt: Frankrijk (5,5%), Europa (18,6%), Verenigde Staten (43%), Noord-Amerika (1,6%) en andere (31,3%).
Aantal werknemers: 86 088
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Biopharma
88,0
%
| 30 688 | 71,4 % | 37 890 | 88,0 % | +23,47% |
Consumer Healthcare
12,0
%
| 5 080 | 11,8 % | 5 180 | 12,0 % | +1,97% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 18 275 | 42,5 % | 18 512 | 43,0 % | +1,30% |
Rest of the World
26,1
%
| 8 386 | 19,5 % | 11 254 | 26,1 % | +34,20% |
Europe
18,6
%
| 7 703 | 17,9 % | 8 013 | 18,6 % | +4,02% |
China
6,8
%
| 3 123 | 7,3 % | 2 912 | 6,8 % | -6,76% |
France
5,5
%
| 2 296 | 5,3 % | 2 379 | 5,5 % | +3,61% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01-09-19 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 01-01-22 |
Chief Tech/Sci/R&D Officer | 51 | - | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-16 |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 49 | 11-09-23 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-19 |
Arnaud Delépine
IRO | Public Communications Contact | - | - |
Raj Verma
PRN | Corporate Officer/Principal | - | 01-12-20 |
- | - | ||
Corporate Officer/Principal | 62 | 01-01-15 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01-05-14 |
Lise Kingo
BRD | Director/Board Member | 62 | 28-04-20 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22-05-20 |
Frédéric Oudéa
CHM | Chairman | 60 | 02-09-22 |
Rachel Duan
BRD | Director/Board Member | 52 | 28-04-20 |
Antoine Yver
BRD | Director/Board Member | 66 | 03-05-22 |
Carole Ferrand
BRD | Director/Board Member | 53 | 03-05-22 |
Paul Hudson
CEO | Chief Executive Officer | 56 | 01-09-19 |
Director/Board Member | 58 | 30-04-19 | |
Emile Voest
BRD | Director/Board Member | 64 | 03-05-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 264 799 969 | 1 100 464 483 ( 87,01 %) | 13 450 388 ( 1,063 %) | 87,01 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
SANOFI 1.28% | 16 245 648 | 1.28% | 1 595 920 473 $ |
SANOFI INDIA LIMITED 60.40% | 13 909 587 | 60.40% | 1 353 934 300 $ |
EUROAPI 29.77% | 28 298 074 | 29.77% | 85 420 566 $ |
MEIRAGTX HOLDINGS PLC 7.39% | 4 697 737 | 7.39% | 28 515 264 $ |
LAVA THERAPEUTICS N.V. 7.30% | 1 919 455 | 7.30% | 6 391 785 $ |
ENENTO GROUP OYJ 0.12% | 29 249 | 0.12% | 545 225 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Chattem, Inc.
Chattem, Inc. Pharmaceuticals: MajorHealth Technology Chattem, Inc. engages in the manufacture of over-the-counter health and beauty care products. It makes anti-dandruff shampoos, medicated skin care, topical pain care, oral care and internal over-the-counter products. The firm distributes its products to mass merchandisers, drugstores and food retail channels. The company was founded by Zeboim Cartter Patten on February 21, 1879 and is headquartered in Bridgewater, NJ. |
Pharmaceuticals: Major
|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. |
Medical Specialties
|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Aventis, Inc.
| |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. |
Pharmaceuticals: Major
|
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. |
Pharmaceuticals: Major
|
Sanofi-aventis Ireland Ltd.
Sanofi-aventis Ireland Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Ireland Ltd. manufactures pharmaceutical products for cardiovascular, central nervous system, metabolic disorders, cardiometabolic, oncology, thrombosis, and vaccines. The company is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Sanofi-Aventis Europe SAS
Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the private company is Jérôme Contamine. |
Pharmaceuticals: Major
|
Genzyme Therapeutic Products LP
Genzyme Therapeutic Products LP BiotechnologyHealth Technology Part of Sanofi, Genzyme Therapeutic Products LP is a private company that specializes in biological products except diagnostic substances. The company is based in Boston, MA. |
Biotechnology
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,70% | 124 mld. | |
+33,25% | 704 mld. | |
+28,59% | 577 mld. | |
-3,55% | 348 mld. | |
+18,16% | 327 mld. | |
+4,36% | 288 mld. | |
+14,81% | 234 mld. | |
+4,93% | 198 mld. | |
-9,78% | 194 mld. | |
-3,69% | 147 mld. |